Moderna's Vaccine Technology Continues to be Tangled in Patent Challenges

With all eyes on Moderna over the leading progress of its vaccine against COVID-19, the company lost an attempt at invalidating a U.S. patent owned by Arbutus Biopharma. A U.S. Patent and Trademark Office administrative court rejected Moderna’s arguments that Arbutus’s ‘069 patent should be revoked because it “described obvious concepts,” according to Reuters.